ENDRA Life Sciences receives Nasdaq delisting notice for insufficient stockholders' equity

ENDRA Life Sciences Inc.

Stockholders' equity of $1,752,885 as of March 31, 2025, below Nasdaq's $2.5M minimum.
Nasdaq letter received May 27, 2025; company has until July 11, 2025 to submit a compliance plan.
If plan accepted, company has until November 23, 2025 to regain compliance.
Failure could lead to delisting; company intends to take measures to regain compliance, but no assurance given.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.